{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-015497","form_type":"8-K","ticker":"SNGX","cik":"0000812796","company_name":"SOLIGENIX, INC.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.636379+00:00","generated_at":"2026-06-23T00:33:33.522276+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Soligenix invited by BARDA to submit $25M contract proposal for Ebola/Marburg vaccines","bullets":["BARDA invites Soligenix to submit full contract proposal for SuVax and MarVax vaccines.","Program valued up to $25M over 5 years for SuVax Phase 1 studies, with options for MarVax.","SuVax demonstrated 100% protection in non-human primate model with 3-dose series.","No protective vaccines currently available for Sudan ebolavirus or Marburg marburgvirus.","Contract award not guaranteed; requires favorable technical review and negotiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-015497","json":"https://secwatch.observer/filing/0001558370-22-015497.json","markdown":"https://secwatch.observer/filing/0001558370-22-015497.md","text":"https://secwatch.observer/filing/0001558370-22-015497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/812796/000155837022015497/0001558370-22-015497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/812796/000155837022015497/tmb-20221027x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:33:33.522276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}